Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Cancer immunoediting: from immunosurveillance to tumor escape

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270

CTLA-4–Ig regulates tryptophan catabolism in vivo

Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Immunotherapy of Metastatic Melanoma

Jinga, D.-C., & Jinga, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105585 · Cited by 1

Imaging mass cytometry in preclinical studies of lung cancer

van Maldegem, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822213-3.00004-8 · Cited by 1

Interleukin-21 and Cancer Therapy

Davis, I. D., Skak, K., Hunder, N. N. H., Smyth, M. J., & Sivakumar, P. V. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_3 · Cited by 1

Developmental Therapeutics for Gynecologic Cancers: An Overview

Brown, J., & Chu, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-32907-9_6 · Cited by 1

New Horizons from Novel Therapies in Malignant Pleural Mesothelioma

Sayan, M., Mamidanna, S., Eren, M. F., Daliparty, V. M., Mustafayev, T. Z., Nelson, C., Ohri, N., Jabbour, S. K., Mert, A. G., & Atalar, B. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0103 · Cited by 1

Therapeutic antibody development—Remington chapter

Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1

Cytokine-Based Therapy for Cancer

Koon, H. B., & Atkins, M. B. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_20 · Cited by 1

Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention

Oble, D. A., Hodi, F. S., Lauwers, G. Y., Dranoff, G., & Mihm, M. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_24 · Cited by 1

Systemische Therapie des metastasierten Melanoms

Eigentler, T., Meier, F. E., Keilholz, U., Hauschild, A., & Garbe, C. (2010) · Der Onkologe · doi:10.1007/s00761-010-1926-3 · Cited by 1

Treatment of Disseminated Melanoma

Chang, J., Ott, P. A., & Pavlick, A. C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1788-4.00057-5 · Cited by 1

Management of Dysplastic Nevi and Melanomas

Huang, C. L., Marghoob, A. A., & Halpern, A. C. (2005) · Elsevier eBooks · doi:10.1016/b978-0-323-02752-6.50055-9 · Cited by 1

New Approaches for Optimizing Melanoma Vaccines

Vohra, N. A., Pilon‐Thomas, S., Mulé, J. J., & Weber, J. S. (2008) · CRC Press eBooks · doi:10.3109/9781420020328.011 · Cited by 1

CTLA-4 inhibitor: ipilimumab for the treatment of NSCLC

Brahmer, J. R. (2012) · doi:10.2217/ebo.12.28 · Cited by 1

Autoimmune Hypophysitis

Crock, P., Bensing, S., Smith, C. J. A., Burns, C., & Robinson, P. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-517-6_15 · Cited by 1

Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy

Pardoll, D. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50078-x

Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma

Inman, B. A., Frigola, X., Dong, H., Yang, J. C., & Kwon, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_21

Immune-Suppressive Mechanisms and Cancer: Understanding the Implications, Paradoxes, and Burning Questions

Hurwitz, A. A., & Gabrilovich, D. I. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_1

Investigating the role of PD-L1 pathway in human ovarian cancer

Chatterjee, J. (2014) · doi:10.25560/25119

Tumorvakzinierung beim metastasierten Nierenzellkarzinom

Heine, A., Holderried, T. A. W., & Brossart, P. (2010) · Onkopipeline · doi:10.1007/s15035-010-0176-6

Antibodies in Phase I/II/III: Cancer Therapy

Deckert, P. M. (2007) · doi:10.1002/9783527619740.ch25

Co‐Administration of Co‐Stimulatory Moieties

Arancibia-Cárcamo, C. V., & Latchman, Y. E. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch25

Immunotoxicology of Biopharmaceutics

Haggerty, H. G., Price, K., & Shenton, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00629-1

Immunomodulatory Molecules of the Immune System

Saenger, Y. M., Jenq, R. R., & Perales, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_5

MELANOMA: NARROWING THE SIGHTS ON AN EVASIVE ENEMY

Kefford, R. F. (2006)

Cancer vaccines: a clinical perspective

Dangoor, A., Thistlethwaite, F. C., & Hawkins, R. E. (2006) · British Journal of Hospital Medicine · doi:10.12968/hmed.2006.67.7.21621

Anti-CTLA-4 Monoclonal Antibodies

Yang, A. S., & Wolchok, J. D. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_14

Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

Bol, K. F., Schreibelt, G., Aarntzen, E. H. J. G., de Vries, I. J. M., & Figdor, C. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_4

Immunomodulation in Dermatology

Pomerantz, R. G., Kupper, T. S., & Qureshi, A. A. (2010) · Springer eBooks · doi:10.1007/978-3-540-78814-0_4

Autoimmune hypophysitis in a patient successfully treated with anti-ctla-4 (Ipilimumab) immunotherapy for metastatic malignant melanoma

Sutton, R. A., Voskoboynik, M., McArthur, G. A., & Lokan, J. (2013) · Pathology · doi:10.1097/01.pat.0000426945.15005.b4

Incidence of lung pathology in the dissecting room: a valuable teaching asset

Soh, W. M., & Ellis, H. (2013) · Pathology · doi:10.1097/01.pat.0000426943.07381.be

Cancer immunotherapy with blocking of immune checkpoints

Udono, H. (2013) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.125.13

A Review on Immunotherapy against Cancer

Geresu, M. A. (2016) · Journal of Health, Medicine and Nursing

ANTICUERPOS MONOCLONALES EN EL TRATAMIENTO DEL CÁNCER. TERAPIA DIRIGIDA PARA TUMORES SÓLIDOS

Fuenmayor, J., Hoyos, R. G., & Montaño, R. F. (2013) · Redalyc (Universidad Autónoma del Estado de México)

Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future

Kato, K. (2015) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.61.601

Autoantibody targets in autoimmune polyendocrine syndrome type 1 and lymphocytic hypophysitis.

Smith, C. J. A. (2010) · NOVA (University of Newcastle Australia)

Targeting regulatory T cells and other strategies to enable cancer vaccines

Paustian, C. C., Jensen, S. M., Church, S., Puri, S., Twitty, C., Hu, H., Curti, B. D., Urba, W. J., Puri, R. K., & Fox, B. A. (2013) · CRC Press eBooks · doi:10.3109/9781841848303-15

The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer

Karoutsos, P., Karoutsos, D., & Karoutsou, E. (2017) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000281

State of the Science

Agarwala, S. S. (2007) · Oncology Issues · doi:10.1080/10463356.2007.11883340

Molecular Basis for Treating Cutaneous Melanoma

Ernstoff, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00042-1

Immune Checkpoint Inhibitors in Sarcoma

D’Angelo, S. P., & Kelly, C. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-93530-0_7

Monoclonal Antibodies

Robert, C. (2013) · doi:10.1002/9781118590638.ch23

Checkpoint Inhibitors in the Treatment of Metastatic Melanoma

Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_39-1

CTLA-4 et Toll-like récepteurs: de nouvelles cibles en immunothérapie

Bedel, R., Borg, C., & Saas, P. (2008) · Springer eBooks · doi:10.1007/978-2-287-36008-4_12

Human Antibodies from Transgenic Mice

Lönberg, N. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch5

Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View

Gogas, H. J., Diamantopoulos, P. T., & Polyzos, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-18797-2_2

Regulation of Anti-tumor Immunity in Colorectal Cancer by Interaction of Exosome Immune Complexes with Fc gamma Receptors

McNamara, A. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-5838-dr52

Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm

Syed, S. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_2

Fcγ receptors—Master regulators of antibody therapy

Beers, S. A., & Frendéus, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822028-3.00014-5

Inhibition of JAK3/STAT3 Activation in Rats Uterine Leiomyoma by formula of Taohong Siwu Decoction: A Randomized Controlled TrialPreprint

Luo, L., Shi, S., Zhang, L., Xu, X., Peng, F., Yu, C., Li, L., & Zheng, T. (2021) · Research Square · doi:10.21203/rs.3.rs-786708/v1

Endocrinopathies Associated With Immune Checkpoint Inhibitors

Girotra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00024-7

Practical Management of Melanoma

Naylor, M. F. (2009) · Springer eBooks · doi:10.1007/978-0-387-88495-0_15

Rôle de l'Oncostatine M sur les mélanomes métastatiques et étude des mécanismes de résistance à cette cytokine

Lacreusette, A. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)

Neutrophil activation induces peripheral immunosuppression in glioblastoma and stroke

Berger, T. R. (2013) · doi:10.25677/fmzs-7757

Checkpoint Blockade and Combinatorial Immunotherapies

Peggs, K. S., Quezada, S. A., & Allison, J. P. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_16

Cancer Immunotherapy

Sharma, P., Subudhi, S. K., Peggs, K. S., Goswami, S., Gao, J., Quezada, S. A., & Allison, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068

Checkpoint Inhibitors in the Treatment of Metastatic Melanoma

Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_39

Frontiers in Cancer Immunotherapy

Murphy, J. F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_1

Immunotoxicology of Biopharmaceutics☆

Haggerty, H. G., Price, K., & Shenton, J. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02008-0

Production de cellules dendritiques pour une immunothérapie anti-tumorale

Royer, P. (2006)

Faculty Opinions recommendation of Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Droz, J. P., & Boyle, H. J. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717948504.793453555

Immuntherapie

Peschel, C. (2010) · Springer eBooks · doi:10.1007/978-3-642-03808-2_25

Overcoming Cancer Tolerance with Immune Checkpoint Blockade

Myers, J. W., Peoples, G. E., & Clifton, G. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_6

Immunotherapy

Reinmuth, N., & Heigener, D. F. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010814

Management of Dysplastic Nevi and Melanomas

Marghoob, A. A., Kovalyshyn, I., & Halpern, A. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-06575-7.00043-2

Melanoma

Lange, J. R., Fecher, L. A., Sharfman, W. H., Alani, R. M., Mikkilineni, R., Topalian, S. L., & Balch, C. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50077-4

Tremelimumab

Beljanski, V. (2009) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.64486-1

A microRNA Profile of Human CD8+ Regulatory T cells and Characterization of the Effects of microRNAs on Treg Cell-Associated Genes

Jebbawi, F., Fayyad‐Kazan, H., Merimi, M., Lewalle, P., Fayyad‐Kazan, M., Rachidi, W., Merched, A. J., Alannan, M., Verougstraete, J.-C., Léo, O., et al. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/imcac.1.2020.2

Tumor Vaccines for Breast Cancer

Anderson, K. S. (2007) · Translational medicine series · doi:10.3109/9781420019940.024

Targeting regulatory T cells and other strategies to enable cancer vaccines

Paustian, C. C., Jensen, S. M., Church, S., Puri, S., Twitty, C., Hu, H., Curti, B. D., Urba, W. J., Puri, R. K., & Fox, B. A. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.014

Immunotherapy in gynecologic malignancies

Renz, M., & Dorigo, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00026-x

Monoclonal Antibody and Targeted Toxin Therapy

Bast, R. C., & Zalutsky, M. R. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm065.pub2

Data from Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

Nevala, W. K., Vachon, C. M., Leontovich, A. A., Scott, C. G., Thompson, M. A., & Markovic, S. N. (2023) · doi:10.1158/1078-0432.c.6517534.v1

Data from Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

Nevala, W. K., Vachon, C. M., Leontovich, A. A., Scott, C. G., Thompson, M. A., & Markovic, S. N. (2023) · doi:10.1158/1078-0432.c.6517534

Immunotherapy for Melanoma

Pectasides, E., & Gogas, H. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_150

Biomaterials‐Based Vaccinatio in Cancer Therapy

Sharma, R., Malviya, R., & Sundram, S. (2023) · Wiley eBooks · doi:10.1002/9781394175635.ch14

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib StudyPreprint

Lian, B., Li, J., Si, L., Chi, Z., Mao, L., Wang, X., Tang, B., Yan, X., Li, S., Zhou, L. Q., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4645176

Immune Checkpoint Inhibitors: Novel Therapies and Targets

Baloyan, E., Sargsyan, A., Bedirian, K., Papyan, R., Tamamyan, G., & Bardakhchyan, S. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_258

Immunotoxicology of Biopharmaceutics

Haggerty, H. G., Price, K., & Shenton, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.50043-6

Terapias combinadas contra tumores murinos: inmunoterapia y quimioterapia. Relación de la eficacia del tratamiento con el estado inmunológico del portador

Maglioco, A. (2011) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)

Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer

Gerdemann, U., & Brenner, M. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_1

Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease

Tarhini, A. A., & Kirkwood, J. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976117.031

RNA Interference of CTLA4 in Human Leukaemia T Cells

Vassileva, R. (2013) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/d7r595

Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer

Lv, S., Huang, S., Li, L., Lin, K. L., Zhang, H. Q., & Huang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1766463

Caractérisation anatomo-clinique et phénotypique des adénocarcinomes canalaires du pancréas avec instabilité des microsatellites

Lupinacci, R. M. (2017) · doi:10.70675/f5537d9ezcd37z45ddzb27ez9d26e852f638

Génération de nanobodies pour des applications en immunothérapie

Colazet, M. (2018) · doi:10.70675/ffdc304cz5934z4dd1z9bc5zce2e3dc1ef5a

Hétérogénéité et mécanismes d’initiation de la réponse humorale dans les tumeurs du sein et de l’ovaire

Couillault, C. (2019) · theses.fr (ABES) · doi:10.70675/843d4729zb881z4e85z9bf5z1adbd72f3e7a

Identification of Biomarkers Associated With the Combination of Immunotherapy and Anti-Angiogenic Drugs in the Treatment of Mesothelioma : Translational Analyses of the PEMBIB Clinical Trial Combining the Anti-PD1 Monoclonal Antibody Embrolizumab and the Anti-Angiogenic Tyrosine Kinase Inhibitor Nintedanib

Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725

Rôle de la maturation des précurseurs protéiques par les convertases dans la réponse immunitaire anti-tumorale

François, A. (2023) · theses.fr (ABES) · doi:10.70675/9de3f722zafc2z40a0za6e8z8f7c7cc0450b

Transforming cancer treatment through immunotherapy innovations

Mukherjee, S., Pramanick, A., & Bariar, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44181-3.00013-8

Neuroregulation as a modulatory force in immune checkpoint inhibitor resistance: mechanistic neuro-immune crosstalk informing biomarker-led diagnosis and targetable therapeutic sensitization

Ma, M., Hu, G., Hao, Y., Yu, H., Mou, R., & Jia, Y. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109124

Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer

Weber, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_16

Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies

Camacho, L. H., Ribas, A., Glaspy, J. A., Lopez‐Berestein, G., Reuben, J. M., Parker, C., Seja, E., Comı́n-Anduix, B., Bulanhagui, C. A., & Gómez-Navarro, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2505 · Cited by 19

Anti-CTLA4 antibody clinical trials in melanoma

Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

Ribas, A., Bozon, V. A., Lopez‐Berestein, G., Pavlov, D., Reuben, J. M., Parker, C., Seja, E., Glaspy, J. A., Gómez-Navarro, J., & Camacho, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7524 · Cited by 31

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Dorazio, P., Healey, D. I., Pavlov, D., & Saltz, L. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3035 · Cited by 6

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

Ribas, A., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Navarro, J. G., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3000 · Cited by 38